Detail akcie Catalyst Pharm online

Business Summary: Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Catalyst Pharmaceuticals Inc revenues increased 30% to $288M. Net income increased 70% to $108.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Development and commercialiatization drug products segment income increase of 59% to $129.7M.